Trading JournalBought on the potential breakout,
Not a relative strength leader ( but it was one of the stocks that was breaking out, market could continue to go higher so took a chance)
Sold for -2.5% loss
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−5.56 USD
−749.57 M USD
305.21 M USD
174.61 M
About Insmed Incorporated
Sector
CEO
William H. Lewis
Headquarters
Bridgewater
Website
Founded
1988
FIGI
BBG000BWM5P3
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
INSM accumulation or distribution?I assume distribution. Hard to value a 1-approved-drug bio company with a not-yet-commercialized cure for a self-described 'rare condition' at 13B .
Also usually when things go up a lot they come down a bit first?
INSM - June 24 Qullamaggie Breakout and Episodic Pivot15 June
Price surfing the 10SMA and making lower highs
There are two large momentum candles bringing price above the consolidation.
It was also one of the rare stocks that was green while the broader market was red
Risk
I know the reason for the new pricing but I am unable to determine if it is so
Insmed Catapults 113% on Positive ASPEN Study ResultsInsmed ( NASDAQ:INSM ), a biotech company, has successfully developed a lung disease drug, brensocatib, which has been shown to significantly reduce the frequency of respiratory symptoms such as chronic cough in a late-stage study. The drug, which is expected to be launched in mid-2025, is expected
INSM Cash Secured putThis looks intriguing as premium for CSPs are very high considering most expectations are upbeat.
Insmed Incorporated (INSM: NASDAQ)Insmed Incorporated (INSM), a biopharmaceutical company, is showing positive developments in its product portfolio. The company reiterated its 2023 guidance, expecting revenue between $295-305 million, with strategic plans to expand the use of its ARIKAYCE product.
Encouraging Phase 2 data for its
$INSM Setting UpNASDAQ:INSM earning coming up Thursday but one to keep an eye on.
Nice volume pattern ahead of that event.
Long | INSMNASDAQ:INSM
Possible Scenario: LONG
Evidence: Price Action, Money Flow
Period: Less than two months.
TP1: 28.5$
TP2: 29.5$
TP3: 31$
*This is my idea and could be wrong 100%.
INSM ShortI see a repeating divergence in INSM for a decent short play after this market maker finishes with a target of 7.50
Big Potential For INSMED Daily
Hey guys, INSMED is in a bullish push with high volume buy executed and a water-carrying candle shape followed by short legs. The TIMEFRAME M1 shows us a kind of hammer candle with a high negotiated sales volume, it wanted to bounce back from the bollinger base. But it was a failure passing on its
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of INSM is 70.53 USD — it has decreased by −0.08% in the past 24 hours. Watch Insmed Incorporated stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Insmed Incorporated stocks are traded under the ticker INSM.
INSM stock has fallen by −2.76% compared to the previous week, the month change is a −5.44% fall, over the last year Insmed Incorporated has showed a 137.00% increase.
We've gathered analysts' opinions on Insmed Incorporated future price: according to them, INSM price has a max estimate of 105.00 USD and a min estimate of 75.00 USD. Watch INSM chart and read a more detailed Insmed Incorporated stock forecast: see what analysts think of Insmed Incorporated and suggest that you do with its stocks.
INSM reached its all-time high on Aug 30, 2000 with the price of 199.38 USD, and its all-time low was 2.64 USD and was reached on Nov 25, 2011. View more price dynamics on INSM chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
INSM stock is 1.45% volatile and has beta coefficient of 0.73. Track Insmed Incorporated stock price on the chart and check out the list of the most volatile stocks — is Insmed Incorporated there?
Today Insmed Incorporated has the market capitalization of 12.63 B, it has decreased by −0.47% over the last week.
Yes, you can track Insmed Incorporated financials in yearly and quarterly reports right on TradingView.
Insmed Incorporated is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
INSM earnings for the last quarter are −1.27 USD per share, whereas the estimation was −1.20 USD resulting in a −5.64% surprise. The estimated earnings for the next quarter are −1.18 USD per share. See more details about Insmed Incorporated earnings.
Insmed Incorporated revenue for the last quarter amounts to 93.42 M USD, despite the estimated figure of 93.36 M USD. In the next quarter, revenue is expected to reach 97.61 M USD.
INSM net income for the last quarter is −220.52 M USD, while the quarter before that showed −300.61 M USD of net income which accounts for 26.64% change. Track more Insmed Incorporated financial stats to get the full picture.
No, INSM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 912.00 employees. See our rating of the largest employees — is Insmed Incorporated on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Insmed Incorporated EBITDA is −692.92 M USD, and current EBITDA margin is −219.64%. See more stats in Insmed Incorporated financial statements.
Like other stocks, INSM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Insmed Incorporated stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Insmed Incorporated technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Insmed Incorporated stock shows the buy signal. See more of Insmed Incorporated technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.